Dogwood Therapeutics (DWTX) Price & Analysis

Compare

242 Followers

DWTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.62 - $29.28

Previous CloseN/A

Volume14.38K

Average Volume (3M)17.87K

Market Cap

$10.55M

Enterprise Value$96.56M

Total Cash (Recent Filing)$13.40M

Total Debt (Recent Filing)$75.85M

Price to Earnings (P/E)―

Beta3.30

Next Earnings

Nov 06, 2025

EPS Estimate

-1.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.99

Shares Outstanding1,911,128

10 Day Avg. Volume25,565

30 Day Avg. Volume17,866

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.04

Price to Sales (P/S)0.00

P/FCF Ratio-0.29

Enterprise Value/Market Cap9.15

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-2.08K

Enterprise Value/Ebitda-3.98

Forecast

1Y Price Target

$20.00

Price Target Upside262.32% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial EnrollmentThe P2b CINP trial crossed the 50% enrollment mark, indicating good progress in the study.

Clinical Trial ProgressThe upcoming interim results from the Phase 2b study of Halneuron, a key catalyst for Dogwood, are expected to influence the company's prospects significantly.

Drug EfficacyPharmacology studies revealed that Halneuron is a more potent analgesic than standard agents like aspirin or morphine.

Bears Say

Financial PerformanceThe company reported no revenues in the quarter and a net loss of $1.99 per share, which was worse than the consensus estimated net loss of $0.79 per share.

Financial PositionDogwood reported a net loss of $3.8M, which impacts its financial position.

Dogwood Therapeutics News

Dogwood secures royalty free license to develop, commercialize SP16

Dogwood (DWTX) Therapeutics announced that in an all-stock transaction, it has secured a royalty free, global license to...

15h ago

DWTX

Dogwood Therapeutics Secures Licensing Deal with Serpin Pharma

Dogwood Therapeutics ( ($DWTX) ) has shared an announcement. On September 29, 2025, Dogwood Therapeutics entered into an...

15h ago

DWTX

Buy Rating for Dogwood Therapeutics: Promising Phase 2b Study Results and Strategic Financial Positioning

H.C. Wainwright analyst Sean Lee CFA has maintained their bullish stance on DWTX stock, giving a Buy rating...

1M ago

DWTX

Dogwood Therapeutics Reports Q2 2025 Financial Results

Virios Therapeutics, Inc. ( ($DWTX) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

DWTX

Dogwood reports Q2 EPS ($1.99) vs ($1.15) last year

“With no FDA approved treatments to manage the neuropathic pain often resulting from chemotherapy treatment, we have the...

2M ago

DWTX

Dogwood Therapeutics Approves CFO Salary Increase

Dogwood Therapeutics ( ($DWTX) ) has provided an announcement. On June 27, 2025, Dogwood Therapeutics, Inc. announced that...

3M ago

DWTX

Dogwood Therapeutics Approves Equity Plan Amendment

Dogwood Therapeutics ( ($DWTX) ) just unveiled an announcement. On June 18, 2025, Dogwood Therapeutics, Inc. held its...

3M ago

DWTX

Dogwood files $150M mixed securities shelf

17:27 EDT Dogwood (DWTX) files $150M mixed securities shelf Published first on TheFly – the ultimate source for...

4M ago

DWTX

Promising Growth Potential for Dogwood Therapeutics with Halneuron’s Development and Strong Financial Position

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Dogwood Therapeutics (DWTX...

5M ago

DWTX

Buy Rating for Dogwood Therapeutics Driven by Promising Clinical Developments and Strong Financial Outlook

Dogwood Therapeutics (DWTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

5M ago

DWTX

Dogwood Therapeutics Reports Progress in Pain Treatment Trials

Virios Therapeutics, Inc. ( ($DWTX) ) has released its Q1 earnings. Here is a breakdown of the information...

5M ago

DWTX

Dogwood reports Q1 EPS ($8.45) vs. ($1.68) last year

“There are no FDA approved treatments to manage the neuropathic pain often resulting from chemotherapy treatment,” said Greg...

5M ago

DWTX

Dogwood sees cash runway through 1Q26

Cash on hand of $17.5M provides operational runway through Q1 2026. Published first on TheFly – the ultimate...

5M ago

DWTX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

5M ago

DYN

ANVS

DWTX FAQ

What was Dogwood Therapeutics’s price range in the past 12 months?

Dogwood Therapeutics lowest stock price was $1.62 and its highest was $29.28 in the past 12 months.

What is Dogwood Therapeutics’s market cap?

Dogwood Therapeutics’s market cap is $10.55M.

When is Dogwood Therapeutics’s upcoming earnings report date?

Dogwood Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 37 days.

How were Dogwood Therapeutics’s earnings last quarter?

Dogwood Therapeutics released its earnings results on Aug 13, 2025. The company reported -$1.99 earnings per share for the quarter, missing the consensus estimate of -$0.79 by -$1.2.

Is Dogwood Therapeutics overvalued?

According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dogwood Therapeutics pay dividends?

Dogwood Therapeutics does not currently pay dividends.

What is Dogwood Therapeutics’s EPS estimate?

Dogwood Therapeutics’s EPS estimate is -1.17.

How many shares outstanding does Dogwood Therapeutics have?

Dogwood Therapeutics has 1,911,128 shares outstanding.

What happened to Dogwood Therapeutics’s price movement after its last earnings report?

Dogwood Therapeutics reported an EPS of -$1.99 in its last earnings report, missing expectations of -$0.79. Following the earnings report the stock price went down -1.031%.

Which hedge fund is a major shareholder of Dogwood Therapeutics?

Currently, no hedge funds are holding shares in DWTX

Company Description

Dogwood Therapeutics

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Dogwood Therapeutics (DWTX) Earnings & Revenues

Historic Earnings Reports

DWTX Stock 12 Month Forecast

Average Price Target

$20.00

▲(262.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","31":"$31","9.25":"$9.25","16.5":"$16.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Oct<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.81,6.747692307692308,8.685384615384615,10.623076923076923,12.560769230769232,14.498461538461537,16.436153846153847,18.373846153846156,20.31153846153846,22.24923076923077,24.186923076923076,26.124615384615385,28.062307692307694,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.81,5.978461538461538,7.146923076923077,8.315384615384616,9.483846153846155,10.652307692307694,11.820769230769232,12.989230769230769,14.157692307692308,15.326153846153847,16.494615384615386,17.663076923076925,18.831538461538464,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.81,5.209230769230769,5.608461538461539,6.007692307692308,6.406923076923077,6.806153846153846,7.205384615384615,7.604615384615385,8.003846153846155,8.403076923076924,8.802307692307693,9.201538461538462,9.600769230769231,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.88,"date":1698796800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.54,"date":1709251200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >